24/7 Market News Snapshot 09 July, 2025 – Evoke Pharma, Inc. (NASDAQ:EVOK)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NASDAQ:EVOK) are discussed in this article.
Evoke Pharma, Inc. (NASDAQ:EVOK) is currently experiencing a substantial surge in its stock performance, with pre-market trading showing a notable increase of 21.95%, reaching a price of $3.244 compared to the previous close of $2.660. This bullish trend is accompanied by impressive trading volume, amounting to 774.56K shares, suggesting a robust interest from investors. The upward momentum has prompted analysts to predict potential further advances in the company’s stock, as it surpasses key resistance levels.

Simultaneously, Evoke Pharma has made significant strides in enhancing its intellectual property portfolio surrounding GIMOTI® (metoclopramide) nasal spray. The company has announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for an application that pertains to the use of GIMOTI® in treating diabetic gastroparesis. This allowance expands the existing protections of U.S. Patent No. 11,517,545, ensuring that GIMOTI® remains protected until the patent’s expiration in December 2036, thereby solidifying its market exclusivity.

The company’s CEO, Matt D’Onofrio, emphasized the significance of this patent allowance, stating it not only strengthens the GIMOTI® franchise but also reinforces Evoke’s commitment to addressing the unmet medical needs of patients suffering from diabetic gastroparesis. The company is positioning GIMOTI® as a vital non-oral treatment option for patients who often struggle to absorb oral medications due to gastric complications.

With GIMOTI® being the only FDA-approved non-oral formulation of metoclopramide, Evoke Pharma is dedicated to enhancing treatment experiences for patients. The company will also participate in Gastroparesis Awareness Month this August, aiming to increase awareness and improve treatment options for those living with this chronic condition. As the stock rallies and developments unfold, Evoke Pharma looks poised for a positive trajectory in the pharmaceutical landscape.

Related news for (EVOK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.